Blindness of clinical evaluators, parents, and children in a placebo-controlled trial of fluvoxamine

Benedetto Vitiello, Mark Davis, Laurence L. Greenhill, Daniel S. Pine

Research output: Contribution to journalArticle

Abstract

Objective: Few of the increasing number of pediatric clinical trials of selective serotonin reuptake inhibitors (SSRIs) in children have been evaluated for level of blindness of investigators, children, and parents. The success of the masking procedures used in a double-blind, pediatric trial of fluvoxamine in children was examined. Method: Clinical evaluators, parents, and children were asked to guess individual treatment assignment at the end of an 8-week, placebo-controlled trial of fluvoxamine conducted in 128 outpatients (6-17 years of age) with anxiety disorders. The relationship between treatment attribution and improvement status or presence of adverse events was examined. Results: The rate of correct guesses was significantly greater than chance among clinical evaluators (78%), parents (81%), and children (67%) (for all, p <0.001). Attribution to fluvoxamine was associated with presence of clinical improvement, and attribution to placebo with lack of improvement (p <0.001) in both the fluvoxamine and placebo group. There was no association between presence of adverse events and direction of the guess. Accuracy of the guess did not improve with time. Conclusions: The tendency to attribute improvement to active treatment and lack of improvement to placebo was consistent across investigators, parents, and children and was applied regardless of actual treatment received by the patient. Adverse events did not influence treatment attribution.

Original languageEnglish (US)
Pages (from-to)219-225
Number of pages7
JournalJournal of Child and Adolescent Psychopharmacology
Volume16
Issue number1-2
DOIs
StatePublished - Feb 2006
Externally publishedYes

Fingerprint

Fluvoxamine
Blindness
Parents
Placebos
Research Personnel
Pediatrics
Therapeutics
Serotonin Uptake Inhibitors
Anxiety Disorders
Outpatients
Clinical Trials

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Pediatrics, Perinatology, and Child Health
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Blindness of clinical evaluators, parents, and children in a placebo-controlled trial of fluvoxamine. / Vitiello, Benedetto; Davis, Mark; Greenhill, Laurence L.; Pine, Daniel S.

In: Journal of Child and Adolescent Psychopharmacology, Vol. 16, No. 1-2, 02.2006, p. 219-225.

Research output: Contribution to journalArticle

Vitiello, Benedetto ; Davis, Mark ; Greenhill, Laurence L. ; Pine, Daniel S. / Blindness of clinical evaluators, parents, and children in a placebo-controlled trial of fluvoxamine. In: Journal of Child and Adolescent Psychopharmacology. 2006 ; Vol. 16, No. 1-2. pp. 219-225.
@article{d59415405ae0445d9673bc71ff273ac4,
title = "Blindness of clinical evaluators, parents, and children in a placebo-controlled trial of fluvoxamine",
abstract = "Objective: Few of the increasing number of pediatric clinical trials of selective serotonin reuptake inhibitors (SSRIs) in children have been evaluated for level of blindness of investigators, children, and parents. The success of the masking procedures used in a double-blind, pediatric trial of fluvoxamine in children was examined. Method: Clinical evaluators, parents, and children were asked to guess individual treatment assignment at the end of an 8-week, placebo-controlled trial of fluvoxamine conducted in 128 outpatients (6-17 years of age) with anxiety disorders. The relationship between treatment attribution and improvement status or presence of adverse events was examined. Results: The rate of correct guesses was significantly greater than chance among clinical evaluators (78{\%}), parents (81{\%}), and children (67{\%}) (for all, p <0.001). Attribution to fluvoxamine was associated with presence of clinical improvement, and attribution to placebo with lack of improvement (p <0.001) in both the fluvoxamine and placebo group. There was no association between presence of adverse events and direction of the guess. Accuracy of the guess did not improve with time. Conclusions: The tendency to attribute improvement to active treatment and lack of improvement to placebo was consistent across investigators, parents, and children and was applied regardless of actual treatment received by the patient. Adverse events did not influence treatment attribution.",
author = "Benedetto Vitiello and Mark Davis and Greenhill, {Laurence L.} and Pine, {Daniel S.}",
year = "2006",
month = "2",
doi = "10.1089/cap.2006.16.219",
language = "English (US)",
volume = "16",
pages = "219--225",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "1-2",

}

TY - JOUR

T1 - Blindness of clinical evaluators, parents, and children in a placebo-controlled trial of fluvoxamine

AU - Vitiello, Benedetto

AU - Davis, Mark

AU - Greenhill, Laurence L.

AU - Pine, Daniel S.

PY - 2006/2

Y1 - 2006/2

N2 - Objective: Few of the increasing number of pediatric clinical trials of selective serotonin reuptake inhibitors (SSRIs) in children have been evaluated for level of blindness of investigators, children, and parents. The success of the masking procedures used in a double-blind, pediatric trial of fluvoxamine in children was examined. Method: Clinical evaluators, parents, and children were asked to guess individual treatment assignment at the end of an 8-week, placebo-controlled trial of fluvoxamine conducted in 128 outpatients (6-17 years of age) with anxiety disorders. The relationship between treatment attribution and improvement status or presence of adverse events was examined. Results: The rate of correct guesses was significantly greater than chance among clinical evaluators (78%), parents (81%), and children (67%) (for all, p <0.001). Attribution to fluvoxamine was associated with presence of clinical improvement, and attribution to placebo with lack of improvement (p <0.001) in both the fluvoxamine and placebo group. There was no association between presence of adverse events and direction of the guess. Accuracy of the guess did not improve with time. Conclusions: The tendency to attribute improvement to active treatment and lack of improvement to placebo was consistent across investigators, parents, and children and was applied regardless of actual treatment received by the patient. Adverse events did not influence treatment attribution.

AB - Objective: Few of the increasing number of pediatric clinical trials of selective serotonin reuptake inhibitors (SSRIs) in children have been evaluated for level of blindness of investigators, children, and parents. The success of the masking procedures used in a double-blind, pediatric trial of fluvoxamine in children was examined. Method: Clinical evaluators, parents, and children were asked to guess individual treatment assignment at the end of an 8-week, placebo-controlled trial of fluvoxamine conducted in 128 outpatients (6-17 years of age) with anxiety disorders. The relationship between treatment attribution and improvement status or presence of adverse events was examined. Results: The rate of correct guesses was significantly greater than chance among clinical evaluators (78%), parents (81%), and children (67%) (for all, p <0.001). Attribution to fluvoxamine was associated with presence of clinical improvement, and attribution to placebo with lack of improvement (p <0.001) in both the fluvoxamine and placebo group. There was no association between presence of adverse events and direction of the guess. Accuracy of the guess did not improve with time. Conclusions: The tendency to attribute improvement to active treatment and lack of improvement to placebo was consistent across investigators, parents, and children and was applied regardless of actual treatment received by the patient. Adverse events did not influence treatment attribution.

UR - http://www.scopus.com/inward/record.url?scp=33645832187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645832187&partnerID=8YFLogxK

U2 - 10.1089/cap.2006.16.219

DO - 10.1089/cap.2006.16.219

M3 - Article

VL - 16

SP - 219

EP - 225

JO - Journal of Child and Adolescent Psychopharmacology

JF - Journal of Child and Adolescent Psychopharmacology

SN - 1044-5463

IS - 1-2

ER -